CIA
BMRN icon

Concurrent Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Concurrent Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$807K Buy
14,106
+6,572
+87% +$360K 0.01% 1131
2026
Q1 		$426K Buy
7,534
+1,817
+32% +$106K ﹤0.01% 1299
2025
Q4 		$340K Buy
+5,717
New +$311K ﹤0.01% 1322

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Concurrent Investment Advisors's BMRN Position: Q2 2026 in Review

Concurrent Investment Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 87% in Q2 2026, buying an estimated $360K and bringing the position to 14,106 shares worth $807K. The position accounts for 0.01% of the portfolio, ranked #1131.

Concurrent Investment Advisors first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Concurrent Investment Advisors held 14,106 shares of BioMarin Pharmaceuticals worth $807K as of Q2 2026.
  • Concurrent Investment Advisors bought 6,572 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $360K.
  • BioMarin Pharmaceuticals made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1131 holding.
  • Concurrent Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.